OREGA Biotech (France)

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

Ivan Perrot, Henri‐Alexandre Michaud, Marc Giraudon-Paoli et al. · Cell Reports · 2019 · 416 citations · Full text

Medicine, Oncology, Pharmacology +17

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Emeric Limagne, Romain Euvrard, Marion Thibaudin et al. · Cancer Research · 2016 · 261 citations

Medicine, Immunology, Oncology +16

Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

Jérémy Bastid, Anne Regairaz, Nathalie Bonnefoy et al. · Cancer Immunology Research · 2014 · 250 citations

Medicine, Immunology, Oncology +17

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2

Stéphanie Cochaud, Jérôme Giustiniani, Clémence Thomas et al. · Scientific Reports · 2013 · 146 citations · Full text

Medicine, Immunology, Oncology +17

Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism

Patrik Sundström, Hanna Stenstad, Veronica Langenes et al. · Cancer Immunology Research · 2016 · 73 citations · Full text

Life Sciences, Immunology, Oncology +15